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Brefeldin A: The Advantage Minireview
of Being Uncompetitive
of brefeldin A action might have important implications
for drug discovery.
By what mechanism does brefeldin A inhibit Arf1 ex-
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change factors? The characterization of the mutations
present in GEA1 alleles resistant to brefeldin A shows
that the altered positions are clustered on a region ofBrefeldin A is a small hydrophobic compound produced
the Sec7 domain overlapping with, or very close to, theby toxic fungi that has dramatic effects on mammalian
Arf1-binding site (Peyroche et al., 1999). Therefore, thecells. Within minutes of brefeldin A treatment the Golgi
most likely molecular explanation would be that brefel-complex disassembles and redistributes into the endo-
din A competes with Arf for binding to the Sec7 guanineplasmic reticulum (ER): this makes it a potent inhibitor
nucleotide exchange domain. If this were the case, itof secretion, and a very useful tool for cell biologists.
would be a rare example of a small molecule success-What is the molecular basis of these remarkable effects?
fully blocking a protein:protein interaction. For this rea-Brefeldin A inhibits some of the proteins that activate
son, the mechanism of brefeldin A action has been ofADP-ribosylation factors (Arfs; Donaldson et al., 1992;
great interest in the context of drug discovery as wellHelms and Rothman, 1992). Small G proteins of the
as basic biology. However, when Anne Peyroche andArf family, in their active GTP-bound form, recruit and
Bruno Antonny tested this mechanism, they discoveredassemble protein complexes (the ªcoatsº) that partici-
that, unexpectedly, brefeldin A stabilizes an Arf:Sec7pate in the selection of the desired set of cargo mole-
domain complex rather than preventing its formation.cules and act as scaffolds to drive the budding of small
This prompted detailed biochemical studies that havemembrane vesicles from donor membranes (reviewed
now shown that brefeldin A is an uncompetitive inhibitor:by Schekman and Orci, 1996; see also Springer et al.,
it binds to the transient complex formed between Arf-1999 and Roth, 1999, this issue of Cell). Vesicles budding
GDP and the Sec7 domain, leading to an abortive Arf-from the ER fuse to form the intermediate compartment
GDP:brefeldin A:Sec7 domain complex. In other words,where a very active sorting takes place. Proteins that
brefeldin A makes endogenous Arf1-GDP behave as aneed to be secreted will progress by cisternal maturation
ªdominant negativeº that traps the exchange factor andand/or anterograde vesicular transport through the
blocks activation of other Arf1 molecules by this particu-Golgi, whereas proteins that need to be retrieved to the
lar exchange factor (Figure 1).ER will be sorted into retrograde vesicles for recycling
How Exchange Factors and the ªDominant-Negativeº(reviewed by Glick and Malhotra, 1998). Formation of
Mutants of Small G Proteins Workthese vesicles depends on the assembly of the COPI
The guanine nucleotide exchange factors (GEFs) forcoat by Arf1-GTP. Inhibition of Arf1 leads to the release
small G proteins first recognize the GDP-bound proteinof the COPI coat and many other peripheral membrane
and lower the affinity for GDP, leading to a nucleotide-proteins into the cytosol and ultimately results in the
free transition state. GTP then enters the empty guanine-collapse of the Golgi and its redistribution into the ER
binding site and induces a conformational change that(Dascher and Balch, 1994; Sciaky et al., 1997).
displaces the GEF (see Figure 7 of Peyroche et al., 1999).Yeast cells are usually impermeable, and thus resis-
For Ras, and probably for most other G proteins, thistant, to brefeldin A, but in permeable, mutant strains,
last step is rate limiting for the exchange reaction and thebrefeldin A blocks secretion and has dramatic effects
release of Ras-GTP (Lenzen et al., 1998). The structure ofon Golgi morphology, as it does in mammalian cells. In
the nucleotide-free form of Ras in complex with the Sosyeast, two proteins, Gea1 and Gea2, play an essential
RasGEF domain has been solved, providing importantrole in the early steps of Golgi trafficking. These proteins
insights on the details of these three steps (Boriack-contain a region of approximately 200 amino acids that
Sjodin et al., 1998). Extensive use has been made ofis similar to a domain of Sec7, a protein required for ER
mutant forms of Ras where serine 17 is replaced bythrough Golgi transport in yeast. This ªSec7 domainº
asparagine (RasN17); the corresponding mutations indisplays guanine nucleotide exchange activity for Arf1
related G proteins (Rac, Rho, etc.) have also been widely(Chardin et al., 1996). Cathy Jackson's group has now
used to dissect signal transduction pathways. Theseshown that in yeast, the effects of brefeldin A on the
mutant proteins act as dominant negatives, blockingsecretory pathway are mainly due to the inhibition of
activation of endogenous Ras proteins by upstream ac-the Gea1, Gea2, and Sec7 proteins (Peyroche et al.,
tivators. In the RasN17 mutant, the affinity for GTP is1999).
decreased by three orders of magnitude compared toMammalian cells contain at least three classes of Arf
wild-type Ras; thus, GTP is no longer able to bind andexchange factors with high, moderate, or low sensitivity
displace the GEF, resulting in an abortive complex be-to brefeldin A. The collapse of the Golgi complex caused
tween nucleotide-free RasN17 and the GEF. Becauseby brefeldin A is most likely due to the inhibition of Arf
exchange factors are usually expressed at lower levelsexchange factors; however, it is not clear which ones
than their target G proteins, low levels of RasN17 pro-are the most important targets that explain the morpho-
teins are sufficient to sequester all exchange factorslogical effects of brefeldin A in mammalian cells. This
into abortive complexes, preventing endogenous Rasaspect will be discussed briefly here; in this minireview,
we would like to propose that the molecular mechanism activation.
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their yeast counterparts, but their regulation is poorly
understood. Finally, there is the EFA-6 family of ex-
change factors that work preferentially on Arf6, the most
distantly related member of the Arf family, and play an
important role in early steps of endocytosis, and/or regu-
lated exocytosis and actin cytoskeleton rearrangements
at the plasma membrane (Franco et al., 1999). Mamma-
lian cells of different origin have very different sensitivi-
ties to brefeldin A. For instance, in epithelial MDCK cells,
the Golgi complex is surprisingly resistant to brefeldin
A, but the AP-1/clathrin coat±dependent formation of
vesicles on the trans-Golgi network, en route to the
basolateral cell surface, is affected by brefeldin A (Or-
zech et al., 1999), suggesting that Arf exchange factors
with different sensitivities to brefeldin A control the for-
mation of these different organelles.
Interestingly, Arno, which has a Sec7 domain with a
structure very similar to that of Gea2 (Goldberg, 1998),
is much less sensitive to brefeldin A, indicating an exqui-
site specificity. Furthermore, the characterization of the
mutations in brefeldin A±resistant mutants of Gea1 de-
fines the site of brefeldin A action on the ªSec7 domain.º
Figure 1. Proposed Mechanism of Brefeldin A Inhibition Four residues appear to be critical for brefeldin A sensi-
(Top) Arf with GDP bound (orange), switch 1 region (light blue), and tivity: when these positions of Arno or Cytohesin (resis-
switch 2 region (dark blue) are the major sites of interaction with the tant) are changed to the side chains of Gea1 or p200
Sec7 domain (BeÂ raud-Dufour et al., 1998; Goldberg, 1998). (Bottom) (sensitive), Arno or Cytohesin become much more sensi-
Sec7 domain, major residues implicated in Arf1 interaction are in tive to brefeldin A (Peyroche et al., 1999; Sata et al.,
light blue, residues implicated in brefeldin A sensitivity in yellow,
1999). Thus, the precise site where brefeldin A bindsresidues implicated in both are green. Phenylalanine 190 (corre-
might be known soon, and the structure of the Arf-sponding to a tyrosine in Gea), one of the key residues that determine
GDP:brefeldin A:Sec7 domain complex is most likelysensitivity, is indicated. Brefeldin A (modeled in red on the left) binds
to the Arf-GDP/Sec7 domain complex, probably close to the yellow/ accessible to crystallographic analysis. These studies
green region of the Sec7 domain (helices H and I in the structure). might help to design analogs of brefeldin A that would
be active on the Arno or EFA6 families and that might
inhibit regulated exocytosis and thereby control inflam-Different Arf Exchange Factors Have Different
mation or possibly inhibit the entry of some pathogens.Sensitivities to Brefeldin A
Trapping Proteins in a ªDead-Endº Complex:
There are at least four distinct families of Arf exchange
A New Concept for Drug Discovery?
factors, activating Arf1 or other members of the Arf fam-
The unexpected discovery that brefeldin A inhibits Arf1
ily at different steps of the secretory and endocytic path-
activation by trapping the exchange reaction in a dead-
ways. All of them share a common Sec7 domain that is end complex may have profound implications on the
responsible for the exchange activity and whose struc- development of drugs targeting other exchange factors
ture has recently been solved (Cherfils et al., 1998; Mos- for small G proteins, and possibly in different biological
sessova et al., 1998). A docking model for Arf-GDP on systems as well. The more obvious approach of search-
the Sec7 domain has also been proposed (BeÂ raud- ing for compounds that inhibit protein:protein interac-
Dufour et al., 1998) and the structure of a nucleotide-free tions competitively has intrinsic problems. A small mole-
Arf:Sec7 domain complex has been solved (Goldberg, cule is unlikely to bind to a target protein with the same
1998). However, the motifs flanking this Sec7 exchange affinity and specificity as its protein partner and is there-
domain are different in each family, suggesting different fore unlikely to be an effective competitor. An inhibitor
modes of regulation. The ªsmallº exchange factors (47 that binds to a specific site on a protein complex in an
kDa) of the Arno/Cytohesin/GRP1 family contain an uncompetitive manner might be more efficient. Also, it
N-terminal coiled coil, a central Sec7 domain with a low seems that brefeldin A takes advantage of the re-
sensitivity to brefeldin A, and a C-terminal PH domain arrangements that occur in the Arf-GDP:Sec7 domain
that binds PIP3 (or PIP2). The PH domain is responsible complex while GDP is released. The concentration re-
for recruiting Arno to the membrane in response to sig- quired for a drug to intercalate during this conforma-
nals that increase PIP3 (or PIP2) levels, possibly in a tional rearrangement might be lower than the con-
late stage of regulated secretion (Venkateswarlu et al., centration required to saturate a protein target with a
1998). Proteins in two other families of exchange factors competitive inhibitor.
are much larger: bovine p200 is more closely related to Might this mechanism be useful for other targets of
yeast Sec7 and is highly sensitive to brefeldin A (Mori- drug discovery? Brefeldin A±sensitive Arf1 exchange
naga et al., 1997), whereas GBF1 is more closely related factors themselves may not be useful targets: they play
to yeast Gea1 and Gea2 (Mansour et al., 1998) and con- a major role in constitutive secretion and brefeldin A is
fers resistance to brefeldin A when overexpressed in therefore rather toxic for most cells. However, inhibitors
mammalian cells (Yan et al., 1994). GBF1 and p200 are of exchange factors for other small G proteins, such as
Ras or Rac and Rho, might have therapeutic value. Forthought to function in ER-through-Golgi transport, as
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hydrophobic than brefeldin A. However, Soisson et al. Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J., and
Jackson, C.L. (1999). Mol. Cell 3, 275±285.(1998) have suggested that the C-terminal part of the
Dbl domain of Sos, the region linking it to the PH domain, Qiu, R.G., Chen, J., Kirn, D., McCormick, F., and Symons, M. (1995).
Nature 374, 457±459.or perhaps this PH domain itself, could be involved in
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ciation but inhibits GTP hydrolysis in a subsequent step.
Furthermore, the principle of searching for small mole-
cules that stabilize other types of protein:protein interac-
tions might be worth exploring as a new approach to
other potential therapeutic targets. For example, a com-
pound that stabilizes the interaction between oncogenic
Ras and GAP might be an effective way of blocking
transformation. Moreover, a compound that stabilizes
the interaction between MEK and ERKs might block
signal transduction by trapping ERKs in the cytoplasm.
Considering the number of protein:protein interactions
that make attractive targets for intervention, and the
comprehensive failure of efforts to find small molecules
by conventional inhibitor screens, a new approach may
be justified.
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